The DOI matches its Crossref record; 217 of the 218 references it cites were found in a registry or an index.
Combination cancer immunotherapies tailored to the tumour microenvironment
Abstract
Evidence suggests that cancer immunotherapy will be a major part of the combination treatment plan for many patients with many cancer types in the near future. There are many types of immune processes involving different antitumour and tumour-promoting leucocytes, and tumour cells use many strategies to evade the immune response. The tumour microenvironment can help determine which immune suppressive pathways become activated to restrain antitumour immunity. This includes immune checkpoint receptors on effector T-cells and myeloid cells, and release of inhibitory cytokines and metabolites. Therapeutic approaches that target these pathways, particularly immune-checkpoint receptors, can induce durable antitumour responses in patients with advanced-stage cancers, including melanoma. Nevertheless, many patients do not have a good response to monotherapy approaches and alternative strategies are required to achieve optimal therapeutic benefit. These strategies include eliminating the bulk of tumour cells to provoke tumour-antigen release and antigen-presenting cell (APC) function, using adjuvants to enhance APC function, and using agents that enhance effector-cell activity. In this Review, we discuss the stratification of the tumour microenvironment according to tumour-infiltrating lymphocytes and PD-L1 expression in the tumour, and how this stratification enables the design of optimal combination cancer therapies tailored to target different tumour microenvironments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the other hand, some positive factors such as immunogenic cancer cell death, immunosupportive cytokines, and professional antigen presentation cells (pAPCs) contribute to immune clearance [21].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [21]
Citations
Cites
4 retracted
Items 201–217 of 217
Kroemer, G., Galluzzi, L., Zitvogel, L., & Fridman, W. H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1058597 · Cited by 73
Radiotherapy Complements Immune Checkpoint Blockade
Ngiow, S. F., McArthur, G. A., & Smyth, M. J. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.015 · Cited by 73
Self-citationHost B7x Promotes Pulmonary Metastasis of Breast Cancer
Abadi, Y. M., Jeon, H., Ohaegbulam, K. C., Scandiuzzi, L., Ghosh, K., Hofmeyer, K. A., Lee, J. S., Ray, A., Gravekamp, C., & Zang, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202439 · Cited by 69
Hobo, W. A., Norde, W. J., Schaap, N. P., Fredrix, H., Maas, F., Schellens, K., Falkenburg, J. H. F., Korman, A. J., Olive, D., van der Voort, R., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102807 · Cited by 69
Combined Natural Killer T-Cell–Based Immunotherapy Eradicates Established Tumors in Mice
Teng, M. W. L., Westwood, J. A., Darcy, P. K., Sharkey, J., Tsuji, M., Franck, R. W., Porcelli, S. A., Besra, G. S., Takeda, K., Yagita∥, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0941 · Cited by 69
Self-citationHammers, H. J., Plimack, E. R., Infante, J. R., Rini, B. I., McDermott, D. F., Ernstoff, M. S., Voss, M. H., Sharma, P., Pal, S. K., Razak, A. R. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.4516 · Cited by 66
Combining cancer immunotherapy and targeted therapy
Ribas, A., & Wolchok, J. D. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.011 · Cited by 64
Self-citationAnti-CTLA4 antibody clinical trials in melanoma
Ribas, A. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.09.001 · Cited by 51
Self-citationLasaro, M. O., Sazanovich, M., Giles‐Davis, W., Mrass, P., Bunte, R. M., Sewell, D. A., Hussain, S. F., Fu, Y., Weninger, W., Paterson, Y. Y. W., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.88 · Cited by 49
von Scheidt, B., Leung, P. S. K., Yong, M. C. R., Zhang, Y. X., Towne, J. E., Smyth, M. J., & Teng, M. W. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1646 · Cited by 42
Self-citationPegram, H. J., Smith, E. L., Rafiq, S., & Brentjens, R. J. (2015) · Immunotherapy · doi:10.2217/imt.15.6 · Cited by 34
Update on the role of ipilimumab in melanoma and first data on new combination therapies
Maio, M., Giacomo, A. M. D., Robert, C., & Eggermont, A. M. M. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835dae4f · Cited by 30
Leung, J., & Suh, W. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201242 · Cited by 26
Sipuleucel-T for the Treatment of Advanced Prostate Cancer
Frohlich, M. W. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.004 · Cited by 24
HER2-overexpressing breast cancer
Loi, S., de Azambuja, E., Pugliano, L., Sotiriou, C. P., & Piccart, M. J. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834bd4c9 · Cited by 19
Weber, J. S., Gibney, G. T., Yu, B., Cheng, P., Martinez, A. J., Kroeger, J. L., Freed, J., Richards, A. D., Zhao, X., & Schell, M. J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9055 · Cited by 15
Baskar, S., Zhu, Z., Labitigan, R. L. D., Ovanesian, M., Orentas, R. J., Li, S. Q., Marielle, Y. E., Shern, J. F., Dimitrov, D. S., Maris, J. M., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-652 · Cited by 1
Flagged first, then by citations
1 of the 218 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Molecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,965
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,826
Self-citationT-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Metadata
- Authors
- Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L.
- Affiliations
- QIMR Berghofer Medical Research Institute (AU)
- University of California, Los Angeles (US)
- Corresponding author
- Teng, Michele W. L.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2015-11-24
- Volume
- 13
- Issue
- 3
- Pages
- 143-158
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2257916459
- Cited by
- 944
- References
- 218
- Citations by year
- 2026: 28 · 2025: 50 · 2024: 71 · 2023: 82 · 2022: 132 · 2021: 102 · 2020: 134 · 2019: 95 · 2018: 99 · 2017: 89 · 2016: 56 · 2015: 3
- FWCI
- 8.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Kite Pharma
- National Cancer Institute (R35CA197633)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, combination therapy, tumor microenvironment, immune evasion, immune checkpoint receptors, PD-L1, tumor-infiltrating lymphocytes, myeloid cells, inhibitory cytokines, antigen-presenting cells, adjuvants, melanoma
- MeSH terms
- Adjuvants, Immunologic, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Immunotherapy, Neoplasms, Signal Transduction, Treatment Outcome, Tumor Escape, Molecular Targeted Therapy, Tumor Microenvironment, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
